Compare AbCellera Biologics Inc (ABCL) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | VNQI | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $50.76 |
52-Week Low | $2.78 | $43.26 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.50, up 0.38% with mixed technical signals showing a bullish overall trend but bearish moving averages. The ETF offers international real estate diversification with a low 0.12% expense ratio and attractive 4.6% dividend yield. Recent news highlights its cost advantage over competitors and institutional buying interest from Eagle Bay Advisors, which increased its stake by 95.7% in Q4 2025.
VNQI presents a compelling opportunity for yield-seeking investors seeking global real estate exposure at low cost, with recovery potential as global transaction volumes are expected to rise over 10% in 2026. Key risks include currency fluctuations, international economic volatility, and interest rate sensitivity. The ETF's valuation appears reasonable at 11.9x P/E and 0.9x P/B according to Seeking Alpha analysis from May 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
